- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04009954
Post-operative Ileus and Gut Microbiota
Post-operative Ileus of Colorectal Cancer Patients Associated With Perioperative Gut Microbiota
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Postoperative ileus (POI) is a common clinical condition after abdominal surgical procedure, leading to increased patient morbidity and prolonged hospitalisation.
The clinical manifestations include abdominal distension, nausea, vomiting and the inability to pass stools or tolerate a solid diet. In addition to the discomfort experienced by patients, postoperative ileus is also an important risk factor for complications such as wound dehiscence and pulmonary and thromboembolic complications. Ileus was found to be an important predictor of extended postoperative hospital stays and costs in patients undergoing colectomy.
The mechanism of POI is not very clear until now. At the end of the 20th century, the inflammatory-mediated ileus hypothesis was introduced. But the initial trigger of the inflammatory cascade is unclear The innate immune system recognises two large classes of macromolecules: first, those related to pathogens or pathogen-associated molecular patterns (PAMPs), and secondly, molecules released in response to cell damage or damage-associated molecular patterns (DAMPs). The prototype of PAMPs is lipopolysaccharide (LPS), a constituent of the Gram-negative bacterial cell wall. Translocation of microbial products into the intestinal tissue is a well-documented feature in POI. Previous study demonstrate a clear association between colonic transit time, gut microbiota composition and urinary metabolic phenotype. Here the investigators suggest that the perioperative microbiome may contribute to POI. This study apply NGS(next generation sequencing) technique to analyse the composition of the perioperative gut microbiota of CRC(colorectal cancer) patients, then analysis the relationship between the dynamic variation of gut microbiota and POI.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Yunwei Wei, professor
- Phone Number: +86045185553099
- Email: hydwyw11@hotmail.com
Study Contact Backup
- Name: Yang Liu, assistant research fellow
- Phone Number: +8618345180169
- Email: lyang712@icloud.com
Study Locations
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150001
- Recruiting
- First Affiliated Hospital of Harbin Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Requirements of informed consent and assent of participant, parent or legal guardian as applicable
- Patients with colorectal cancer scheduled for radical coloproctectomy and between the age of 35 and 80 years old without considering sex.
- Patients with BMI= 18.5-23.9
Exclusion Criteria:
- Patients with colorectal cancer with distant metastasis
- Chronic renal diseases and hepatic cirrhosis
- Chronic ischemic heart disease with unstable angina, chronic heart failure at class III or IV and acute myocardial infarction in the last 6 months
- Individuals with a history of Chronic diarrhea
- Individuals with a history of Diabetes mellitus
- Individuals with a history of Hypertension
- Individuals with a history of autoimmune diseases
- Use of antibiotics and probiotics 3 mouth before samples collection
- Individuals with a history of abdominal operation due to any reason
- Individuals with any history of cancer other than colorectal cancer
- Individuals with Inflammatory bowel disease
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Delayed transit
CRC patients with delayed gut transit recovery( first time defecation >3 day )
|
Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering "MiSeq" reads into operational taxonomic units (OTUs).
|
Normal transit
CRC patients with normal gut transit recovery( first time defecation <=3 day )
|
Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering "MiSeq" reads into operational taxonomic units (OTUs).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gut microbiome dynamics in colorectal cancer patients during the perioperative period between two groups
Time Frame: The day before operation day, the first to the 10th day after operation (everyday the patient's faeces will be collected for microbiome analysis, if the patient has no faeces,we will skip that day to next day for fecal collection)
|
The diversity, structure of fecal microbiota and relative abundance of special bacterial taxa 16S rRNA gene sequencing will be performed.
|
The day before operation day, the first to the 10th day after operation (everyday the patient's faeces will be collected for microbiome analysis, if the patient has no faeces,we will skip that day to next day for fecal collection)
|
The time ranging from operation day to the day of first defecation
Time Frame: Up to 10 days
|
The recovery of gut transit can be indicated by the first defecation
|
Up to 10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of plasma i-FABP(intestinal fatty acid-binding protein)
Time Frame: The day before operation day, every day from first to fifth post-operative day
|
The detection of i-FABP is useful to determine localized changes in intestinal damage.
|
The day before operation day, every day from first to fifth post-operative day
|
Concentration of plasma LPS
Time Frame: The day before operation day, every day from first to fifth post-operative day
|
The presence of lipopolysaccharide (LPS) has been used as an indirect measurement of bacterial translocation and systemic exposure to bacteria.
|
The day before operation day, every day from first to fifth post-operative day
|
Concentration of fecal LPS
Time Frame: The day before operation day, the first to the 10th day after operation (everyday the patient's faeces will be collected for microbiome analysis, if the patient has no faeces,we will skip that day to next day for fecal collection)
|
LPS was derived from gram-negative bacteria in the intestinal tract, and LPS in blood was derived from feces.
|
The day before operation day, the first to the 10th day after operation (everyday the patient's faeces will be collected for microbiome analysis, if the patient has no faeces,we will skip that day to next day for fecal collection)
|
Concentration of fecal calprotectin
Time Frame: The day before operation day, the first to the 10th day after operation (everyday the patient's faeces will be collected for microbiome analysis, if the patient has no faeces,we will skip that day to next day for fecal collection)
|
Fecal calprotectin is not only an indicator of intestinal inflammation, but also an indicator of intestinal mucosal barrier.
|
The day before operation day, the first to the 10th day after operation (everyday the patient's faeces will be collected for microbiome analysis, if the patient has no faeces,we will skip that day to next day for fecal collection)
|
Collaborators and Investigators
Investigators
- Study Director: Yunwei Wei, First Affiliated Hospital of Harbin Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Yunwei Wei 2019-04-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-operative Ileus
-
The Cleveland ClinicTerminated
-
VA Greater Los Angeles Healthcare SystemCedars-Sinai Medical CenterUnknownPost Operative IleusUnited States
-
Instituto Tecnologico y de Estudios Superiores...Completed
-
G-Tech CorporationEminence Clinical Research, Inc.RecruitingPost-operative IleusUnited States
-
University of Puerto RicoMerck Sharp & Dohme LLCTerminated
-
Azienda Ospedaliera Universitaria Policlinico Paolo...CompletedPost-operative IleusItaly
-
Bausch Health Americas, Inc.Wyeth is now a wholly owned subsidiary of PfizerCompletedPost-Operative Ileus (POI)United States
-
Tioga PharmaceuticalsRTI Health SolutionsTerminated
-
Sheba Medical CenterUnknown
-
Palisade BioRecruitingIleus | Post-Operative AdhesionsUnited States
Clinical Trials on Fecal and blood samples collection for analysis
-
Centre Hospitalier Universitaire de NiceCompletedUrinary Tract InfectionsFrance
-
Wake Forest University Health SciencesRecruiting
-
Xiangya Hospital of Central South UniversityUnknownAcute Respiratory Distress SyndromeChina
-
Centre hospitalier de l'Université de Montréal...CompletedInflammatory Bowel Diseases | Colorectal Cancer | Anastomotic Leak | MicrobiotaCanada
-
Ela ShaiCompletedInherited Platelet DisordersIsrael
-
Jules Bordet InstituteBristol-Myers Squibb; La Fondation contre le cancer, Belgique; Les Amis de l'Institut... and other collaboratorsRecruitingCNS MetastasesBelgium, France, Luxembourg
-
IVI SevillaInstituto Valenciano de Infertilidad, IVI VALENCIA; IVI Madrid; IVI BarcelonaEnrolling by invitationNon-Viable PregnancySpain
-
Rigshospitalet, DenmarkCompleted
-
University of AberdeenRecruitingTakotsubo CardiomyopathyUnited Kingdom
-
University Hospital, Basel, SwitzerlandSwiss Multiple Sclerosis RegistryRecruitingMultiple Sclerosis | COVID-19 (Severe Coronavirus Disease 2019)Switzerland